We thank Katrin Heimlich, Maria Dörner, and Hildegard Bethäuser for technical assistance in the enrichment of CD138-positive plasma cells and Michaela Brough, Stephanie Pschowski-Zuck, and Desireé Kirn for performing interphase fluorescence in situ hybridization analysis.
Autologous retransplantation for patients with recurrent multiple myeloma
A single-center experience with 200 patients
Article first published online: 10 APR 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 13, pages 2438–2446, 01 July 2013
How to Cite
Sellner, L., Heiss, C., Benner, A., Raab, M. S., Hillengass, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H. and Neben, K. (2013), Autologous retransplantation for patients with recurrent multiple myeloma. Cancer, 119: 2438–2446. doi: 10.1002/cncr.28104
- Issue published online: 17 JUN 2013
- Article first published online: 10 APR 2013
- Manuscript Accepted: 7 MAR 2013
- Manuscript Revised: 15 FEB 2013
- Manuscript Received: 31 OCT 2012
- multiple myeloma;
- salvage therapy;
- autologous stem cell transplantation;
Therapeutic options for patients with recurrent multiple myeloma after autologous stem cell transplantation (ASCT) include novel agents, conventional chemotherapy, or salvage ASCT with no standard of care.
A total of 200 patients with multiple myeloma who developed disease recurrence after treatment with upfront ASCT and received an autologous retransplantation as salvage therapy at the study center over a period of 15 years were retrospectively reviewed. The objective of the current study was to evaluate the role of salvage ASCT in terms of efficacy, particularly taking into account the impact of novel agents.
The median progression-free survival (PFS) and overall survival after salvage ASCT were 15.2 months and 42.3 months, respectively. The overall response rate (a partial response or greater) was 80.4% at day 100, excluding 6 patients who died before assessment. Factors associated with improved PFS and overall survival after salvage ASCT included an initial PFS of > 18 months after upfront ASCT, bortezomib-containing or lenalidomide-containing therapies for reinduction, response to reinduction, and an International Staging System stage of I before salvage ASCT.
Salvage ASCT is capable of achieving sustained disease control in patients with multiple myeloma. The use of lenalidomide and bortezomib for reinduction has improved the results after salvage ASCT, suggesting that novel agents and salvage ASCT are complementary rather than alternative treatment approaches. Cancer 2013;119:2438-2446. © 2013 American Cancer Society.